MD3877395T2 - Procedeu industrial pentru prepararea de estetrol de înaltă puritate - Google Patents

Procedeu industrial pentru prepararea de estetrol de înaltă puritate

Info

Publication number
MD3877395T2
MD3877395T2 MDE20210894T MDE20210894T MD3877395T2 MD 3877395 T2 MD3877395 T2 MD 3877395T2 MD E20210894 T MDE20210894 T MD E20210894T MD E20210894 T MDE20210894 T MD E20210894T MD 3877395 T2 MD3877395 T2 MD 3877395T2
Authority
MD
Moldova
Prior art keywords
estetrol
preparation
high purity
industrial process
iii
Prior art date
Application number
MDE20210894T
Other languages
English (en)
Inventor
Robert Lovas
Sandor Maho
Ildiko Bacsa
Beatrix Mayer
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MD3877395T2 publication Critical patent/MD3877395T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invenţia se referă la procedeul de preparare a estetrolului cu formula (I), a derivaţilor acestuia protejaţi la poziţiile 3,15α, 16α, 17β cu formula generală (III) şi a derivaţilor 3-hidroxi ai acestuia protejaţi la poziţiile 15α, 16α, 17β cu formula generală (IV), şi la intermediarii cu formulele generale (III) şi (IV) aplicaţi în procedeul respectiv.
MDE20210894T 2019-09-03 2020-09-02 Procedeu industrial pentru prepararea de estetrol de înaltă puritate MD3877395T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1900315A HU231240B1 (hu) 2019-09-03 2019-09-03 Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
PCT/IB2020/058148 WO2021044302A1 (en) 2019-09-03 2020-09-02 Industrial process for the preparation of high purity estetrol

Publications (1)

Publication Number Publication Date
MD3877395T2 true MD3877395T2 (ro) 2023-05-31

Family

ID=89992977

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20210894T MD3877395T2 (ro) 2019-09-03 2020-09-02 Procedeu industrial pentru prepararea de estetrol de înaltă puritate

Country Status (29)

Country Link
US (1) US11633406B2 (ro)
EP (1) EP3877395B1 (ro)
JP (1) JP7265087B2 (ro)
KR (1) KR20220071206A (ro)
CN (1) CN114302889B (ro)
AU (1) AU2020343497B2 (ro)
CA (1) CA3147815C (ro)
CL (1) CL2022000492A1 (ro)
CO (1) CO2022003769A2 (ro)
CU (1) CU24692B1 (ro)
DK (1) DK3877395T3 (ro)
EC (1) ECSP22022403A (ro)
ES (1) ES2855923T3 (ro)
FI (1) FI3877395T3 (ro)
HR (1) HRP20230230T1 (ro)
HU (2) HU231240B1 (ro)
IL (1) IL290973B2 (ro)
JO (1) JOP20220041A1 (ro)
LT (1) LT3877395T (ro)
MA (1) MA54200B1 (ro)
MD (1) MD3877395T2 (ro)
MX (1) MX2022002603A (ro)
PE (1) PE20221418A1 (ro)
PL (1) PL3877395T3 (ro)
PT (1) PT3877395T (ro)
RS (1) RS63966B1 (ro)
SI (1) SI3877395T1 (ro)
WO (1) WO2021044302A1 (ro)
ZA (1) ZA202203557B (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220348607A1 (en) * 2019-09-27 2022-11-03 Industriale Chimica S.R.L. Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene- 3,15,16,17-tetrol (estetrol) and intermediates of said process
WO2023051937A1 (en) * 2021-10-01 2023-04-06 Industriale Chimica S.R.L. Process for preparing (15alpha,16alpha,17 eta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1390040E (pt) 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
ATE449606T1 (de) 2001-05-23 2009-12-15 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
WO2003041718A1 (en) 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003103684A1 (en) 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
EP1511498B1 (en) 2002-06-11 2012-11-21 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
EP1526856B1 (en) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
DE60332754D1 (de) * 2002-11-08 2010-07-08 Pantarhei Bioscience Bv Synthese von oestetrol aus von oestron abgeleiteten steroiden
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
EP2114412B1 (en) 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
EP2383279A1 (en) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE033590T2 (hu) 2011-08-11 2017-12-28 Estetra Sprl Esztetrol alkalmazása sürgõsségi fogamzásgátlóként
JP6196625B2 (ja) 2011-10-07 2017-09-13 エステトラ エス．ペ．エール．エル． エステトロールを製造するための方法
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
US9988417B2 (en) * 2013-09-18 2018-06-05 Crystal Pharma, S.A.U. Process for the preparation of estetrol
MX369035B (es) 2013-12-12 2019-10-25 Donesta Bioscience B V Unidad de dosificacion solida de disolucion oral que contiene un componente de estetrol.
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
ME03728B (me) 2015-06-18 2021-01-20 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
CA3071660A1 (en) 2017-08-01 2019-02-07 Fund Sa Adjuvant therapy for use in prostate cancer treatment
SG11202007163WA (en) 2018-02-07 2020-08-28 Estetra Sprl Contraceptive composition with reduced cardiovascular effects
US20220348607A1 (en) 2019-09-27 2022-11-03 Industriale Chimica S.R.L. Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene- 3,15,16,17-tetrol (estetrol) and intermediates of said process

Also Published As

Publication number Publication date
PT3877395T (pt) 2023-02-02
HU231240B1 (hu) 2022-04-28
JP2022546016A (ja) 2022-11-02
US11633406B2 (en) 2023-04-25
SI3877395T1 (sl) 2023-03-31
HUE061427T2 (hu) 2023-07-28
CU20220013A7 (es) 2022-10-11
MA54200B1 (fr) 2023-02-28
BR112022003254A2 (pt) 2022-05-17
WO2021044302A1 (en) 2021-03-11
AU2020343497A1 (en) 2022-04-14
HRP20230230T1 (hr) 2023-04-14
CA3147815A1 (en) 2021-03-11
AU2020343497B2 (en) 2023-02-02
IL290973A (en) 2022-05-01
ZA202203557B (en) 2022-11-30
EP3877395B1 (en) 2022-12-07
PE20221418A1 (es) 2022-09-20
ECSP22022403A (es) 2022-04-29
LT3877395T (lt) 2023-02-27
DK3877395T3 (da) 2023-03-06
CO2022003769A2 (es) 2022-04-19
CU24692B1 (es) 2024-01-10
HUP1900315A1 (hu) 2021-03-29
PL3877395T3 (pl) 2023-05-08
IL290973B2 (en) 2023-11-01
ES2855923T3 (es) 2023-04-28
MA54200A (fr) 2022-04-27
ES2855923T1 (es) 2021-09-24
CN114302889A (zh) 2022-04-08
CL2022000492A1 (es) 2023-03-10
CN114302889B (zh) 2023-08-29
MX2022002603A (es) 2022-03-25
RS63966B1 (sr) 2023-03-31
FI3877395T3 (fi) 2023-03-18
JOP20220041A1 (ar) 2023-01-30
IL290973B1 (en) 2023-07-01
EP3877395A1 (en) 2021-09-15
CA3147815C (en) 2023-03-28
KR20220071206A (ko) 2022-05-31
US20220296609A1 (en) 2022-09-22
JP7265087B2 (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
MD3877395T2 (ro) Procedeu industrial pentru prepararea de estetrol de înaltă puritate
CY1118475T1 (el) Αντιοξειδωτικοι ρυθμιστες φλεγμονης: c-17 ομολογοποιημενα παραγωγα ολεανολικου οξεος
WO2016071293A3 (en) Pharmaceutical compound
BR0316470A (pt) Derivados de 3-amino-piperadina e métodos de preparação
EA200901612A1 (ru) Противовоспалительные соединения замещенных циклобутендионов
ECSP10010192A (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios
MX2016004737A (es) Metodo para sintetizar tamices moleculares de silicoaluminofosfato-34.
MX2013006811A (es) Compuestos, composiciones y articulos fotocromaticos.
CO2022003062A2 (es) Compuestos heterocíclicos
MX2016000669A (es) Compuestos plaguicidas.
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
MX2021011980A (es) Composicion de control de artropodos.
IL195766A (en) Phosphinic acids and their sulfur derivatives, methods for their preparation and use as metal extraction materials
MX2022001495A (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
CO2020011855A2 (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
GB201210131D0 (en) Light emitting composition and device
CU24518B1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
UA118269C2 (uk) Промисловий спосіб синтезу уліпристалу ацетату і його 4'-ацетильного аналога
MY179214A (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate
EP4249469A3 (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
WO2015075693A8 (en) Process for the synthesis of (11 beta,17alpha)-17-acetoxy-11 -methyl-19-norpregn-4-en-3,20-dione
BR112021020407A2 (pt) Processo para preparação de intermediários para as sínteses de derivados de vitamina a de polienos por ciclização
MX2017009298A (es) Compuestos de azolobenzazina, composiciones que comprenden estos compuestos, y su uso para controlar plagas de invertebrados.
MD3716952T2 (ro) Forme de dozare cuprizând un inhibitor de kalikreină al plasmatică